KalVista Pharmaceuticals, Inc.

NasdaqGM:KALV 주식 보고서

시가총액: US$540.2m

KalVista Pharmaceuticals 관리

관리 기준 확인 2/4

KalVista Pharmaceuticals' CEO는 Ben Palleiko, Mar2024 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 2.42M, 21.3% 로 구성됩니다. 21.3% 급여 및 78.7% 보너스(회사 주식 및 옵션 포함). 는 $ 2.75M 가치에 해당하는 회사 주식의 0.53% 직접 소유합니다. 2.75M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 4.5 년입니다.

주요 정보

Ben Palleiko

최고 경영자

US$6.8m

총 보상

CEO 급여 비율8.6%
CEO 임기less than a year
CEO 소유권0.6%
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간3.6yrs

최근 관리 업데이트

Recent updates

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Sep 12
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Sep 05

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

Jun 24

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Feb 14

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02
We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

KalVista: Another Setback But The Key Value Driver Is Still In Place

Oct 14

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24
Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

KalVista Pharmaceticals GAAP EPS of -$0.94

Sep 08

KalVista reaches five-month high as rival tumbles on hereditary angioedema

Aug 22

KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11

Jul 07

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Feb 02
Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

Sep 24
We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

Jul 02
We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study

Jun 07

CEO 보상 분석

Ben Palleiko 의 보수는 KalVista Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jul 31 2024n/an/a

-US$142m

Apr 30 2024US$7mUS$580k

-US$127m

Jan 31 2024n/an/a

-US$108m

Oct 31 2023n/an/a

-US$101m

Jul 31 2023n/an/a

-US$95m

Apr 30 2023US$2mUS$515k

-US$93m

Jan 31 2023n/an/a

-US$91m

Oct 31 2022n/an/a

-US$92m

Jul 31 2022n/an/a

-US$89m

Apr 30 2022US$3mUS$490k

-US$82m

Jan 31 2022n/an/a

-US$73m

Oct 31 2021n/an/a

-US$61m

Jul 31 2021n/an/a

-US$52m

Apr 30 2021US$1mUS$435k

-US$46m

Jan 31 2021n/an/a

-US$38m

Oct 31 2020n/an/a

-US$37m

Jul 31 2020n/an/a

-US$33m

Apr 30 2020US$1mUS$435k

-US$29m

Jan 31 2020n/an/a

-US$31m

Oct 31 2019n/an/a

-US$26m

Jul 31 2019n/an/a

-US$23m

Apr 30 2019US$2mUS$366k

-US$21m

Jan 31 2019n/an/a

-US$13m

Oct 31 2018n/an/a

-US$14m

Jul 31 2018n/an/a

-US$16m

Apr 30 2018US$821kUS$340k

-US$16m

보상 대 시장: Ben 의 총 보상 ($USD 6.77M )은 US 시장( $USD 2.44M ).

보상과 수익: 회사가 수익성이 없는 동안 Ben 의 보상이 증가했습니다.

CEO

Ben Palleiko (58 yo)

less than a year

테뉴어

US$6,772,197

보상

Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...

리더십 팀

이름위치테뉴어보상소유권
Benjamin Palleiko
CEO & Directorless than a yearUS$6.77m0.58%
$ 3.1m
Christopher Yea
Chief Development Officer8.9yrsUS$1.37m0.20%
$ 1.1m
Paul Audhya
Chief Medical Officer3.4yrsUS$1.83m0.19%
$ 1.0m
Brian Piekos
Chief Financial Officerless than a year데이터 없음데이터 없음
Ryan Baker
Head of Investor Relationsno data데이터 없음데이터 없음
Brian Krex
General Counselno data데이터 없음데이터 없음
Jarrod Aldom
Vice President of Corporate Communicationsno data데이터 없음데이터 없음
Rachel Morten
Senior Vice President of Regulatory Affairs & QAno data데이터 없음데이터 없음
Michael Smith
Senior Vice President of Development5.4yrs데이터 없음데이터 없음
Nicole Sweeny
Chief Commercial Officer1.3yrs데이터 없음데이터 없음
Stephen Donnelly
Director of Finance and Company Secretaryno data데이터 없음데이터 없음

2.3yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: KALV 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Benjamin Palleiko
CEO & Directorless than a yearUS$6.77m0.58%
$ 3.1m
Edward Unkart
Independent Director9.8yrsUS$136.60k0%
$ 0
Brian J. Pereira
Independent Chairman5.7yrsUS$161.60k0%
$ 0
Nancy Stuart
Independent Director3.6yrsUS$136.60k0%
$ 0
William Fairey
Independent Directorless than a yearUS$143.78k데이터 없음
Tomas Kiselak
Board Observer9.3yrs데이터 없음데이터 없음
Patrick Treanor
Independent Director2.4yrsUS$124.10k0%
$ 0

3.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: KALV 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.